Investment
Features
FeesSafety
Academy
More
Pluang+

Oil prices and 10-year Treasury yields hit strongest correlation since 2019, pressuring markets and inflation.

Market News
14 Sep 2026
CNBC
View Source
Bearish
Oil prices and 10-year Treasury yields hit strongest correlation since 2019, pressuring markets and inflation.

Oil prices and 10-year Treasury yields are moving in near lockstep, with their correlation reaching 0.96—the highest since 2019. This tight relationship is driven by rising oil prices due to Middle East tensions, pushing inflation expectations and Treasury yields higher. The impact tightens financial conditions, raising borrowing costs and pressuring stocks, especially growth and tech sectors. Experts warn this dynamic could lead to more Fed rate hikes and a bond bear market, while consumers face higher energy and loan costs. However, the correlation may ease if geopolitical tensions subside or economic growth concerns increase.

Oil prices and Treasury yields moving closely is the story's subject, with Pluang data providing market context. For readers following US stocks on Pluang as of Sep 15, 2026 09:41 WIB, breadth shows 75 stocks rose and 72 fell among 150 priced. Notable movers include Intel Corp (INTC) down 4.76% at USD 98.04, Salesforce Inc (CRM) up 4.52% at USD 258.91, and Schlumberger NV (SLB) down 4.44% at USD 53.57.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

SPYM ETF charges less than VOO for S&P 500 exposure but tracks multiple indexes historically.

The SPDR Portfolio S&P 500 ETF (SPYM) charges a lower fee of 0.02% compared to Vanguard's VOO at 0.03%, making it slightly cheaper for investors seeking S&P 500 exposure. However, SPYM's long-term performance record is based on four different indexes...

Market News
Neutral
4 hours ago
Newfoundland Discovery Corp. rebrands as Genesis Goldfields Corp. with new ticker GGF on CSE.

Newfoundland Discovery Corp. rebrands as Genesis Goldfields Corp. with new ticker GGF on CSE.

Newfoundland Discovery Corp., a Canadian gold exploration company focused on Angola, has changed its name to Genesis Goldfields Corp. Along with the rebranding, its trading symbol on the Canadian Securities Exchange will change from NEWD to GGF start...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App